Mesenchymal Stem Cell Therapy for Non-Ischemic Cardiomyopathy
Mesenchymal stem cell (MSC) therapy holds promise for non-ischemic cardiomyopathy (NICM), a condition with limited treatment options. MSCs have demonstrated regenerative and immunomodulatory properties, offering potential benefits in improving cardiac function and reducing inflammation. Research has explored the mechanisms and clinical applications of MSC therapy for NICM, providing insights into its therapeutic potential.